INTRODUcTION
Multidrugresistant tuberculosis (MDRTB) that leads to the transmission of resistant strains among the population is a contemporary weakness of TB control programmes [1] . Patients infected with multidrugresistant strains are less likely to be cured [2] . The treatment is much more toxic and expensive (about 700 times the cost) than for patients with drug sensitive organisms [3] . As these patients are difficult to treat, they can remain infectious for a prolonged period and are of great epidemiological importance.
A high prevalence of tobacco use has been noted since 1918 in studies looking at TB risk factors [4] . There appears to be sufficient evidence to conclude that smoking is causally associated with active TB. Taken together, smoking (both current and former, passive and active) appears to increase the risk of being infected with M. tuberculosis and of developing TB, as well as the severity of disease and the risk of death [58] . Feng et al., [9] recently showed in a physiologicallyrelevant animal model that cigarette smoke exposure increased the bacterial burden and inhibited the pulmonary Tcell response , Turan Karagöz in mice infected with M. tuberculosis. Increased risk of TB associated with smoking has been reported to be more prominent among older adults, individuals with a lower education level and those with a history of alcohol consumption [10] . In a study by Wen and colleagues [11] , the mortality rate of smokers was as much as nine times greater than that of people who had never smoked, and quitting lowered the risk substantially. To highlight the importance of smoking cessation in TB management, a recent mathematical modelling analysis projected the effects of tobacco smoking on TB control worldwide. The model estimated that aggressive tobacco control (achieving an annual 1% decrease in smoking prevalence until the point of eradication) would avert 27 million smokingattributable deaths from TB by 2050 [12] .
As reviewed by Slama et al., [5] there are two cohort studies, six casecontrol studies and two crosssectional studies, all of high scientific quality, that have each shown at least one statistically significant relationship between TB and active exposure to tobacco smoke. However, there is insufficient evidence from this body of literature for accurately measuring the effect of passive or active tobacco smoking on the outcome of drug resistant TB, and additional studies are necessary to gauge the influence of this important factor on the disease process. Therefore, the present study was conducted to explore the impact of smoking on the radiological and clinical manifestations, as well as the outcome, of MDRTB.
MATERIAL AND METhODS

Setting and Participants
This was a retrospective study of a cohort that has previously been described [13] . Briefly, participants were hospitalised MDRTB patients treated in our clinic between February 2000 and March 2005. The hospital is located in Istanbul, an area with the highest TB incidence of all cities in its region and it is one of the main referral hospitals for difficult cases from all regions in Turkey.
Diagnosis and Treatment
The patients in this study could be classified into three groups according to their diagnosis and treatment, and all met the criteria for diagnosis of MDRTB [14] .
1. New cases of TB who received 'firstline' drugs under direct observation at the hospital. These medications, as specified by the National TB Control Programme, included isoniazid (H), rifampin (R), pyrazinamide (Z), ethambutol (E) or streptomycin (S) during the initial phase, and H and R during the continuation phase. Patients had a positive smear in the fifth month after initiation of treatment (considered as failure) and resistance against H and R revealed with a drug susceptibility test.
2. New cases of TB who received firstline drugs without direct observation, and whose treatment was considered a failure after a positive smear following an eight month retreatment regimen (2HRZES+1HRZE+5HRE) and due to resistance to at least H and R demonstrated with the initial drug susceptibility test.
3. Patients with history of previous infections (relapse or defaulter) whose treatment was considered a failure after a positive smear following an eight month re treatment regimen (2HRZES+1HRZE+5HRE) and due to resistance to at least H and R demonstrated with the initial drug susceptibility test.
Some MDRTB patients were treated with secondline drugs including aminoglycosides (amikacin, capreomycin), quinolone derivatives (ofloxacin, ciprofloxacin), prothionamide or cycloserine, and firstline drugs (for example, Z and E) were occasionally included in the new regimen if susceptibility was suspected. If quinolone derivatives and prothionamide had already been used in a previous regimen, drugs such as clofazimine, paraaminosalicylic acid (PAS), thioacetazone, amoxicillinclavulanic acid and capreomycin were included in the regimen [15, 16] . Aminoglycosides were administered five days a week until three months after culture conversion. All patients were hospitalised during aminoglycoside administration and received drugs under direct observation.
The duration of treatment for MDRTB cases was 18 months after achieving culture conversion, but this was extended to 24 months if there was no major drug in the regimen. All patients were followed monthly with a sputum smear for acidfast bacilli, LowensteinJensen cultures and a chest Xray (CXR). At the end of the treatment, all patients were evaluated with cultures to evaluate the results. CXRs were reviewed by two pulmonary specialists, and if there was a discrepancy in the interpretation, the case was further reviewed by another chest specialist blinded to the results. The location of lesions and the presence of cavities were recorded.
All patients were given an informed consent document describing the drugs in use, possible adverse affects and the duration of treatment, and they were asked to sign before the initiation of treatment. The study was approved by the local Education and Training Programme Committee of the hospital. HIV serology was performed for every patient.
Definitions
Primary resistance was defined as the presence of resistant isolates of M. tuberculosis in patients who, in response to direct questioning, denied having received any prior antituberculous treatment (for as long as one month). Acquired resistance was defined as the presence of resistant isolates in those who admitted having been treated for TB for one month or more [17] . Radiologic involvement of disease was categorised as extensive or limited according to CXRs. Extensive involvement was defined as one or both of the following; a sum of cavity diameters totalling 15 cm or dense infiltrates involving more than 75% of lung fields [18] .
Treatment outcome was classified as successful (cure) or poor (treatment failure, defaulter or death), and the classification was performed according to the recommendations of the World Health Organization [19] . Cure was defined as a negative smear and cultures throughout at least 18 months of treatment (or 24 months, in the absence of firstline drugs). If only one positive culture was reported during that time, and there was no concomitant evidence of deterioration, a patient was still considered cured if the positive culture was followed by a minimum of three consecutive negative cultures. Treatment failure was defined as persistence of a positive smear and culture despite treatment for 1824 months.
Defaulter was defined as a failure to complete treatment for any
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reason. Death could be for any reason, including TB. Relapse was defined as recurrence of a positive smear or culture after a cure.
In this study, eversmokers included current smokers and ex smokers. A current smoker was defined as a person who smoked daily or occasionally during the treatment, an ex smoker as a person who had quited before visiting the hospital, and a neversmoker as a person who had never smoked. Tobacco smoke exposure was measured according to duration and frequency of exposure and reported in 'packyears'.
Statistical Analysis
Data were analyzed using SPSS for Windows v15.0 statistics program. Differences were evaluated using a Student's ttest for variables with normal distribution and using a Mann Whitney U test for those without. Nominal variables were assessed by the chisquare test, and for all analyses, p<0.05 was considered statistically significant.
RESULTS
Among 103 MDRTB patients evaluated, 81 were male and 22 were female. The mean age of patients was 40.5±13.5
(1472) years. All were HIVnegative. Most patients had only a primary school education (78.6%) and were married (81.6%). Nearly half of the cohort (45.6%) resided outside of Istanbul. A family history of TB was present in 14.6% of cases, and 9.7% had a family member with MDRTB. Primary multidrug resistance was observed in more than one third of cases (39.8%). 28.8% of patients had at least one concomitant disease (Table 1) , most commonly diabetes mellitus or chronic obstructive pulmonary disease (COPD).
Eightynine cases (86.4%) were evaluated in the group with a successful outcome. The group with poor outcome totalled 14 cases (2 defaulters, 4 treatment failures, and 8 deaths). Extensive radiologic involvement was noted in 21.4% of all cases and was more common in the group with poor outcome (p=0.005) ( Table 2) . Among all cases, 40.8% were never smokers, 33% were current smokers, and 26.2% were exsmokers. There was no statistically significant difference in the distribution of smokers among the groups with successful or poor outcomes, but there was a correlation with the level of cigarette consumption between the two groups.
The mean cigarette consumption in the group with a successful outcome was 14.7±19.9 packyears, whereas in the group with poor outcome it was 40.5±44.4 (p=0.0001).
DIScUSSION
Although there is considerable evidence that smoking (both current and former, passive and active) is associated with the risk of being infected with M. tuberculosis, as well as the risk of developing TB, the severity of disease and of death, the specific link between smoking and MDRTB has been largely ignored [512]. Barroso and colleagues examined this in a casecontrol study investigating risk factors for acquired MDRTB, and through univariate analysis they identified an association of smoking with acquired MDRTB [20] . In multivariate analysis ('smoking alone' was excluded), the combination of 'alcoholism and smoking' was associated with acquired MDRTB. Ruddy et al. [21] conducted a crosssectional study to investigate both prevalence and risk factors of drug resistance, and smoking was found to be associated with isoniazid resistance. The authors concluded that more evidence was needed to explain this association.
Previous studies of patients with TB have reported a significantly higher likelihood of default and failure in association with smoking through univariate analyses [22, 23] . Investigators in Hong Kong conducted a casecontrol study to assess risk factors for defaulting from antiTB treatment under a 'directly observed' treatment programme and found that current smokers were significantly more likely to default than never smokers [24] . In studies based on univariate analysis or multivariate analysis controlling for age, gender, family screening, new vs. relapse, smear status, and presence of cough, haemoptysis, or cavity, nonsmokers were significantly more likely to adhere to treatment [2529] . In the cohort study of Qazi et al., [30] current smoking was found as one of the strong predictors of delayed time to culture conversion. Controlling for initial drug resistance, alcoholism, and treatment irregularity, smokers (habitual and current) were significantly more likely to relapse than nonsmokers [29] .
Tobacco smoke has been reported to have various effects on the lung in both animal and human studies. More specifi-95 cally, smoking has been associated with changes in pulmonary macrophages and lymphocytes that play a major role in cellular immunity [31] . Eversmokers were more likely to have evidence of upper zone involvement, cavity and 'miliary' appearance on chest radiographs than nonsmokers [32, 33] . A crosssectional study by AltetGomez et al., [34] revealed that after controlling for confounders including age, sex, alcohol consumption and intravenous drug use, smokers were significantly more likely to have cavitary lesions, positive bacilloscopy and pulmonary TB than nonsmokers.
A limitation of the present study was that the cohort size was insufficient to permit analysis of all risk factors, and this precluded determining the effect of cigarette consumption on treatment outcome of MDRTB through multivariate analysis. Another limitation was that the history of smoking status was selfreported and did not depend on the full definitions in the guidelines. The knowledge about smoking history was limited to the answer of the question "if they were currently smoking or not". However, if there was a responder bias in revealing smoking status, it would in theory make it more likely that smokers be misclassified as nonsmokers and this would lead to an underestimation of the effects of smoking on TB.
In conclusion, understanding the impact of smoking on the outcome of MDRTB is critically important for successful management of the disease. Patients with MDRTB need, and should receive, counselling and assistance in quitting smoking.
Prospective clinical studies are necessary to evaluate if aggressive smoking cessation intervention combined with chemotherapy will improve the survival of patients with MDRTB. 
